# CEJ Capital

> CEJ Capital is a VC fund in Tsukuba backing Medical, Medical Device and Information Technology. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Tsukuba, Japan
- Total investments: 10
- Last investment: Sep 2021
- Lead investor: 10%
- Last updated: Aug 2026

CEJ Capital is a venture capital arm of CYBERDYNE. It engages in the creation of cybernics industry, management, and management of growth promotion investment business association property.

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $7.3M–$425M |
| Series B | $12M–$128M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 5 | 50% |
| Medical Device | 4 | 40% |
| Information Technology | 3 | 30% |
| Nursing and Residential Care | 3 | 30% |
| Software | 2 | 20% |

20 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 30% |
| Series B | 3 | 30% |
| Venture - Series Unknown | 3 | 30% |
| Funding Round | 1 | 10% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| GAIA BioMedicine | GAIA BioMedicine is Based on the intellectual property and technology. | $11.9M | Series B | Sep 21, 2021 |  |
| KanonCure | KanonCure is a research and development company that engages in the discovery and development of regenerative medicine products and pharmaceuticals for liver diseases. The company conducts research in cell therapy and related therapeutic approaches for the treatment, diagnosis, and prevention of severe liver disorders. Its work includes methodsintended to reduce fibrosis associated with cirrhosis and support liver tissue regeneration. | $4.6M | Venture - Series Unknown | Aug 05, 2021 |  |
| Jiksak Bioengineering | Jiksak Bioengineering is a biotechnology company. Jiksak Bioengineering provide an efficient screening service using a three-dimensional cell tissue "Nerve Organoid". We will mainly develop screening technologies specifically for neurodegenerative diseases and search for drugs that are effective for amyotrophic lateral sclerosis (ALS). |  | Series B | Mar 23, 2021 |  |
| ANSeen | ANSeeN implemented a third-party allotment of new shares underwritten by real tech fund. | $8.5M | Series B | Sep 07, 2020 |  |
| AMI Corp | AMI Corp is engaged in medical consulting, medical device development and writing. | $69.5M |  | Apr 20, 2020 |  |
| AMI | AMI Corp is engaged in medical consulting, medical device development and writing. | $4.6M | Venture - Series Unknown | Apr 20, 2020 |  |
| Kringle Pharma | Kringle Pharma, Inc., a biopharmaceutical company, develops pharmaceutical products based on its research on hepatocyte growth factor (HGF) and NK4. Its HGF has the regenerative healing ability in regard to liver cells, as well as various cells and organs; and NK4 is a bi-functional molecule, which inhibits the invasion and metastasis of tumorcells as an HGF-antagonist, as well as possesses antiangiogenic activity. The company’s pipeline includes recombinant human HGF for the treatment of acute renal failure, skin ulcers, and CNS diseases; and recombinant human NK4 and NK4 gene drugs for cancer therapy. Kringle Pharma, Inc. was founded in 2001 and is based in Toyonaka, Japan. | $8.8M | Venture - Series Unknown | Feb 28, 2020 |  |
| bitkey | Bitkey is a company provides its own key technology. | $170.1M | Series A | Jan 23, 2020 |  |
| SmartScan | SmartScan is a Japanese company that manufactures preventive medicines. SmartScan's mission is to create and provide an image screening environment that is easy for anyone to visit. | $7.3M | Series A | Nov 28, 2019 |  |
| LPIXEL | LPIXEL, a spin-out venture from the University of Tokyo, is a leader in advanced image analysis software and systems tailored to life science research. With strong emphasis on integrating top-tier technologies to its services and strong dedication to maximize research efficiency. LPIXEL aims to bring innovation to the world of research. | $425.2M | Series A | Oct 28, 2018 |  |

10 of 10 investments shown.

## Co-investors
- [Cyberdyne](https://shizune.co/investors/profile/cyberdyne) — VC Fund, 6 deals together
- [SBI Investment](https://shizune.co/investors/profile/sbi-investment-2) — VC Fund, 2 deals together
- [Canon Medical Systems](https://shizune.co/investors/profile/canon-medical-systems) — VC Fund, 1 deal together
- [DBJ Capital](https://shizune.co/investors/profile/dbj-capital) — VC Fund, 1 deal together
- [DG VENTURES](https://shizune.co/investors/profile/dg-incubation) — VC Fund, 1 deal together
- [Drone Fund](https://shizune.co/investors/profile/drone-fund) — VC Fund, 1 deal together

## Similar investors

### Similar industry
- [Innova Memphis](https://shizune.co/investors/profile/innova-memphis) — VC Fund
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [Enterprise Ireland](https://shizune.co/investors/profile/enterprise-ireland) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Mitsubishi UFJ Capital](https://shizune.co/investors/profile/mitsubishi-ufj-capital) — VC Fund
- [SMBC Venture Capital](https://shizune.co/investors/profile/smbc-venture-capital) — VC Fund
- [Mizuho Capital](https://shizune.co/investors/profile/mizuho-capital) — VC Fund

## Featured in investor lists
- [Medical Device Investors in Japan](https://shizune.co/investors/medical-device-investors-japan)
- [Medical Device VC Funds in Japan](https://shizune.co/investors/medical-device-vc-funds-japan)

## FAQ

### What does CEJ Capital invest in?

CEJ Capital invests primarily in Medical, Medical Device and Information Technology startups, most often at Series A and Series B stage. Most of the 10 investments tracked by Shizune back companies in Japan. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is CEJ Capital's check size?

CEJ Capital typically joins rounds of $7.3M–$425M at Series A and $12M–$128M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds CEJ Capital participates in.

### When did CEJ Capital last invest?

The most recent investment recorded for CEJ Capital closed in Sep 2021. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co